Compare DexCom, Inc. (DXCM) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zeta Global Holdings Corp — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Zeta Global Holdings Corp trades at $21.95 (market cap $5.59B). The key difference: DexCom, Inc. is far larger — about 5× Zeta Global Holdings Corp's market cap. Which is the better fit depends on your goals.
| DXCM | ZETA | |
|---|---|---|
Market Cap | $28.06B | $5.59B |
Sector | Health | Technology |
52-Week High | $89.53 | $25.24 |
52-Week Low | $54.84 | $14.55 |
Enterprise Value | $27.03B | $5.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
ZETA trades at $21.74, down 3.51% over 24 hours, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $1.30B in 2025 but a net loss of $31.51M, with improving margins projected for 2026. Recent strategic partnerships with Palantir and OpenAI highlight a pivot toward AI infrastructure, driving positive media sentiment.
The outlook for ZETA is cautiously optimistic, with a consensus price target of $27.50 offering ~27% upside. Investment opportunities stem from AI-driven growth and consecutive earnings beats, but risks include persistent negative profitability, cash flow challenges, and competitive pressures in the marketing tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
